HepB20: Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
Study Details
Study Description
Brief Summary
Vaccination coverage against HBV in France is around 30% in the adult population. Treatment with anti-CD20 is associated with a risk of reactivation of hepatitis B or acute or fulminant hepatitis in first-infected patients. HBV vaccination is recommended as before any anti-CD20 treatment in unimmunized patients.
However, there is no recommendation on which vaccination regimen to choose in patients on immunosuppressants / corticosteroids or with inflammatory or autoimmune disease.
For patients who have a need for rapid immunosuppressive therapy, the use of a standard vaccination schedule (D0, M1, M6) would be responsible for a loss of chance vis-à-vis the underlying disease with a delay of more than 6 months to start treatment with anti-CD20. An accelerated regimen (D0, D7, D21 and M12) allows healthy adults to obtain very rapid vaccine protection between 77 and 90.8%. The accelerated regimen can also be considered on a case-by-case basis in those adults with neurological pathologies, systemic vasculitis or autoimmune disease and who need to receive anti-CD20 antibodies if the combination of injections over a short period is likely to promote immunization.
The advantage of the accelerated regimen is to obtain 4 weeks, after the third dose of vaccine, anti-HBs antibodies at a protective level (> 10 IU / L) in approximately 77 to 90.8% of patients and in the general population. The booster injection at 12 months is essential for long-term protection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
An accelerated regimen allows healthy adults to obtain vaccine protection very quickly. The accelerated regimen can also be considered on a case-by-case basis in those adults with neurological pathologies, systemic vasculitis or autoimmune disease requiring an anti-CD20 monoclonal antibody if the combination of injections over a short period is likely to promote immunization.
The aim of this pilot, interventional study is to evaluate the anti-HBV vaccine response measured by the level of anti-HBs antibodies greater than 10 IU / l after vaccination in patients to receive treatment with anti-CD20.
Evaluation of the specific anti-HBV vaccine response, measured by the level of anti-HBs antibodies greater than 10 IU / l at M2, M6 and M13 in patients having received a regimen accelerated by Engerix B 20 µg (D0, D7, J21), then recall 12 months later. Anti-CD20 drugs should be started at least 1 month after the first 3 injections for neurological pathologies and after the first 2 injections for vasculitis and autoimmune diseases (scheme linked to the underlying pathology with the need for rapid treatment with anti -CD20 in these pathologies).
Follow-up of 3 parallel cohorts of patients seronegative for hepatitis B virus (HBV):
-
1 cohort followed for multiple sclerosis or another inflammatory neurological disease (group 1)
-
the cohort followed for systemic vasculitis (group 2)
-
1 cohort followed for an autoimmune disease (RA, Lupus, etc.) (group 3) to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B.
The patients will be followed for a period of 13 months after the start of the vaccination.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: multiple sclerosis or other inflammatory neurological disease HBV negative |
Biological: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
|
| Experimental: systemic vasculitis HBV negative |
Biological: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
|
| Experimental: an autoimmune disease HBV negative |
Biological: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
|
Outcome Measures
Primary Outcome Measures
- Measure of the specific anti-HBV vaccine response, assessed by the level of anti-HBs antibodies greater than 10 IU / l at M2, M6 and M13 [13 months]
regimen accelerated by Engerix B 20 µg (D0, D7, D21), then recall 12 months later regimen accelerated by Engerix B 20 µg (D0, D7, D21), then recall 12 months later regimen accelerated by HBV vaccine 20 µg (D0, D7, D21), then recall 12 months later
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients over 18 years old
-
Multiple sclerosis or other known neurological disease (group 1), systemic vasculitis (group 2) or autoimmune disease (group 3)
-
Decision on treatment with anti-CD20 (rituximab or ocrelizumab)
-
Free and informed consent, oral
-
Negative hepatitis B serology.
Exclusion Criteria:
-
Previous hepatitis B vaccination
-
Major disability
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Valérie POURCHER | Paris | Ile De France | France | 75013 |
Sponsors and Collaborators
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Investigators
- Principal Investigator: valérie Pourcher, MD, Pitie-Salpetriere Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CREPATS 009